On 26 January 2011 Mylan, the second-largest US generics manufacturer, announced a truce with global pharma giant Pfizer, which will enable the former to sell generic versions of the cholesterol drug Lipitor (atorvastatin) and combination blood pressure and cholesterol treatment Caduet (amlodipine/atorvastatin).
Mylan in and out of hot water
Home/Pharma News
|
Posted 18/03/2011
0
Post your comment

Pfizer sued Mylan early last year for patent infringement, after the company filed an Abbreviated New Drug Application (ANDA) with the FDA. Generic Caduet may be marketed from 30 November 2011, or earlier under ‘certain circumstances’ which both parties are keeping confidential; the agreement itself is subject to review by the US Department of Justice and the Federal Trade Commission. Lipitor’s patent expires later this year and several generic versions are anticipated by November.
Shionogi
On 17 December 2010 Shionogi Pharma filed a patent-infringement lawsuit against Mylan to prevent the generics manufacturer from gaining approval for its version of the anti-inflammatory drug Orapred ODT (prednisolone). The company is seeking an injunction to prevent Mylan from marketing or manufacturing its generic prednisolone until the patent expires in November 2019, in response to the drugmaker's ANDA.
Mylan believes it is the first company to have filed a substantially complete ANDA for this drug containing a Paragraph IV certification for the specified strengths and therefore expects to qualify for 180 days of marketing exclusivity upon final FDA approval. As of January 2011 Mylan had 170 ANDAs pending FDA approval representing US$97.7 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing US$24.2 billion in annual brand sales. These figures are taken from the company website, but quote out-of-date IMS estimates. They nevertheless give the picture of Mylan being very active in pursuing its strategy of ‘first generic to market’ and the website also shows several FDA approvals and launches this year already.
Related articles
Mylan granted US restraining order over sales of paroxetine
Source: IBTimes, Mylan, News-Medical
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment